Does RUCAPARIB Cause Malignant neoplasm progression? 15 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Malignant neoplasm progression have been filed in association with RUCAPARIB. This represents 3.5% of all adverse event reports for RUCAPARIB.
15
Reports of Malignant neoplasm progression with RUCAPARIB
3.5%
of all RUCAPARIB reports
8
Deaths
6
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RUCAPARIB?
Of the 15 reports, 8 (53.3%) resulted in death, 6 (40.0%) required hospitalization, and 2 (13.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUCAPARIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does RUCAPARIB Cause?
Anaemia (49)
Acute kidney injury (34)
Febrile neutropenia (33)
Fatigue (32)
Nausea (30)
Pancytopenia (27)
Diarrhoea (23)
Drug ineffective (22)
Vomiting (20)
Abdominal pain (17)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RUCAPARIB Alternatives Have Lower Malignant neoplasm progression Risk?
RUCAPARIB vs RUCAPARIB CAMSYLATE
RUCAPARIB vs RUFINAMIDE
RUCAPARIB vs RUPATADINE
RUCAPARIB vs RUXOLITINIB
RUCAPARIB vs SABRIL